Oncosil Medical Ltd · ASX:OSL
Oncosil Medical — Corporate Update (July 2018)
24 slides from Oncosil Medical's corporate update, Jul 26, 2018
Slide 1: Company Update: Advancing Pancreatic Cancer Treatment
For personal use only ASX.OSL Company Update July 2018 Advancing Pancreatic Cancer Treatment OncoSil Medical 1
Slide 2: Investment Highlights
OncoSil Medical | Investment Highlights For personal use only 1 Clear Commercialising a breakthrough implantation radiation treatment for mission Pancreatic cancer 2 Current and previous clinical studies demonstrate: Sound Excellent Local Disease Control science Significant reduction in tumour s
Slide 3: OncoSil is a medical device for unresectable locally advanced pancreatic cancer
OncoSil Medical OncoSilTM is a medical device for the treatment of unresectable locally advanced For personal use only pancreatic cancer First in class technology Share price performance (1 year) Proprietary brachytherapy (internal radiation) medical Share price (acps) Volume (m) device Cancer i
Slide 4: About the OncoSil device
About the OncoSilTM device An implantable radiotherapy medical device targeting pancreatic cancer For personal use only OncoSilTM is a single-use brachytherapy device Delivered through Microparticles: 30-micron silicon particles contain beta-emitting Phosphorus-32 (32P) OncoSilTM Microparticles are
Slide 5: Implantation procedure
Implantation procedure Studies continue to show the device implantation is technically straightforward For personal use only Endoscope guided into the OncoSil™ injected OncoSilTM dose is upper intestine directly into the suspended in a tumour Using CT or real-time imaging, specially formulated the n
Slide 6: Real-Time Visualisation
Real-Time Visualisation Needle Positioning in Pancreatic Mass via Endoscopic Ultrasound (EUS) For personal use only Needle positioning OncoSil™ deposition OncoSil Medical 6
Slide 7: SPECT-CT Bremsstrahlung Imaging
SPECT-CT Bremsstrahlung Imaging For personal use only Used to Confirm Localisation of OncoSil™ Coronal Sagittal Transverse CT Interaction of beta particles with SPECT tissue can produce (note: intensity in gray bremsstrahlung x- scale) rays which can be imaged with a gamma camera. Fused Single ‘hot
Slide 8: OncoSil at a potential value inflection point
OncoSil at a potential value inflection point The Company is well positioned to realise value of OncoSil™ device For personal use only Current focus Before 2015: 2016 to 2018: 2018 onwards: Demonstrate Satisfy regulatory Path to potential obligations commercialisation 4 studies show Secured US F
Slide 9: Clinical pathway overview
Clinical pathway overview PanCO and OncoPaC-1 to inform future studies For personal use only Future focus Phases: Current focus Studies to drive clinical adoption (EU & global) 2 concurrent trials, targeting 65 patients total and secure US FDA approval Trials: PanCO – 45 patients Company exploring c
Slide 10: PanCO study – positive results to date
PanCO study – positive results to date Positive clinical data on 35 patients (at Week 8) and 30 patients (at Week 16) For personal use only Study progress overview 50 patients enrolled1 41 patients implanted1 Disease Control Rate (DCR) of 100% Partial Response – a reduction (Week 8) and 87% (Week
Slide 11: Tumours successfully resected
Tumours successfully resected For personal use only Recap of study context Study population drawn 6 implanted patients so far have undergone surgical from patients with resection with curative intent (undergoing the Whipple unresectable locally procedure) advanced pancreatic cancer 5 patients
Slide 12: Substantial tumour volumetric reduction
Substantial tumour volumetric reduction Revamped leadership team For personal use only Best tumour volumetric change in first 35 implanted patients 80 27 of 35 patients (77%) º 60 demonstrated reduction in tumour volume of at least 20% from baseline % change from baseline 40 20 º º º º * º -20 † º -
Slide 13: Significant opportunity for OncoSil
Significant opportunity for OncoSil For personal use only Current available treatment for pancreatic cancer The opportunity for OncoSil Surgery (resection), if diagnosed early enough Only two drugs to have made Chemotherapy (Gemcitabine & Abraxane, FOLFIRINOX) significant improvements in pancr
Slide 14: Positive reception at key conferences
Positive reception at key conferences Early study data presented at 3 leading conferences: European Association of Nuclear Medicine Annual Congress 2017 Digestive Disease Week 2018 For personal use only European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2018 Digest
Slide 15: Partnering with leading cancer centres
Partnering with leading cancer centres 15 leading cancer centres participating in Global Pancreatic Cancer clinical programme For personal use only Region Centre MD Anderson, Texas Johns Hopkins, Maryland Moffit Cancer Centre Florida Cedars Sinai Hospital, LA Guy’s & St Thomas’, London University of
Slide 16: Clear pathway to commercialisation
Clear pathway to commercialisation Strategic partners provide multiple paths to market to optimise value For personal use only Well positioned for commercialisation Potential paths to market Broad technology platform Treatment for multiple solid tumours Strategic licensing partners in all key geogra
Slide 17: Target markets and global opportunity
UK(Launch market) 1,2 Pancreatic cancer 8,747 Liver cancer 4,186 European Union1,2 For personal use only Pancreatic cancer 79,331 Liver cancer 51,785 Target markets Annual incidence China1,2 Global opportunity United States 1,2 Pancreatic cancer 65,727 Liver cancer 351,000 Pancreatic cancer US>$2.0b
Slide 18: Global Commercial opportunity in excess of $2bn
Global Commercial opportunity in excess of $2bn 130,000 cases per year in US+EU alone: more than 70,000 of these could benefit from OncoSil™ For personal use only More than 70,000 relevant Locally OncoSil™ provides a suitable treatment to patients in EU and US alone advanced control the growth of th
Slide 19: Sector M&A trends
Sector M&A trends Over A$2bn of acquisitions in February 2018 highlights attraction of early-stage For personal use only Australian biotech to global pharmaceutical players Acquiree Acquirer Consideration A$1.9 billion1 A$502 million1 A$120 million1 Date 22 May 2018 22 Feb 2018 6 Feb 2018 Premium 78
Slide 20: Board of Directors
Board of Directors For personal use only • Board and management are experienced leaders in the pharmaceutical and medical device space, having held senior positions at Cochlear (ASX:COH), Sirtex Medical (ASX:SRX), ABIVAX, Baxter International, Roche and more • Extensive leadership experience guiding
Slide 21: Highly experienced management team
Highly experienced management team Revamped leadership team For personal use only • Management team experienced leaders in the medical device space having held senior positions at Sirtex Medical (ASX:SRX) • Extensive leadership experience in clinical studies, commercialisation and manufacturing & op
Slide 22: Key catalysts in CY 2018
Key catalysts in CY 2018 Revamped leadership team For personal use only Target CE Mark Certification CE Mark Target EU first sales Completion of PanCO clinical study, with 50 patients currently enrolled Global Pancreatic OncoPaC-1 trial progress: 6 patients currently enrolled Clinical Study
Slide 23: Important notice
Important notice For personal use only This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil or the Company) to provide an overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presenta
Slide 24: Daniel Kenny, CEO & Managing Director
For personal use only Daniel Kenny CEO & Managing Director E: daniel.kenny@oncosil.com.au OncoSil Medical Ltd www.oncosil.com.au T: +61 2 9223 3344 F: +61 2 9252 3988 OncoSil Medical 24